InClinica has experience across all phases of clinical development, with particular strength assisting small to mid-sized companies that are entering first-in-human trials and phase II studies. Our talents, combining late drug discovery and early development experience, make us unique among other clinical CROs and provide significant value to companies in these early clinical phases.
Does that mean we can’t do phase III studies? Hardly. We have — and we are.
Our senior leadership team brings a wealth of experience in drug development and clinical trial management.
Our clinical managers have worked at large CROs and pharmaceutical companies. And, with access to world-class experts who are critical to trial design and execution, we put our experience to work for you.
Our collective experience in drug development is extensive enough to anticipate the common and not so common mistakes, oversights and assumptions that derail studies, in order to keep your program on track.
We bring deep experience in oncology, metabolic disease, and inflammatory diseases, along with experience in diseases as diverse as cardiovascular disease, GI disorders, and infectious disease.
With our team’s track record of timely, successful completion of trials at leading institutions around the world, we invest ourselves fully in your success.